Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

Investigation follows the August 10, 2026 disclosure regarding Tenax Therapeutics, Inc.; investors who lost money may have claims to recover their losses

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation follows the August 10, 2026 disclosure regarding Tenax Therapeutics, Inc.

Investors who lost money on Tenax Therapeutics, Inc. securities can submit their Tenax Therapeutics, Inc. loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the Tenax Therapeutics, Inc. investigation

• Disclosure date: August 10, 2026
• Stock price decline: $12.06 per share, or 89.77%
• Closing price after the decline: $1.38 on August 10, 2026

What happened?

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.

"The price of Tenax Therapeutics, Inc. shares fell 89.77% following the August 10, 2026 disclosure that Tenax's Phase 3 LEVEL trial of TNX-103 had failed to meet its primary endpoint of improved 6-minute walk distance versus placebo or its key secondary endpoint of improved Kansas City Cardiomyopathy Questionnaire total symptom score. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of Tenax Therapeutics, Inc. investors. Investors who lost money can contact Glancy about the Tenax Therapeutics, Inc. investigation, email [e-mail], or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought Tenax Therapeutics, Inc. securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Tenax Therapeutics, Inc. investigation.

What is a securities fraud investigation? In the Tenax Therapeutics, Inc. investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against Tenax Therapeutics, Inc., investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Tenax Therapeutics, Inc. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the Tenax Therapeutics, Inc. investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Tenax Therapeutics, Inc. investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about Tenax Therapeutics, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email [e-mail].

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

• Tenax Therapeutics, Inc. investigation page, Glancy Prongay Wolke & Rotter LLP
• Tenax Press Release
• Tenax Therapeutics, Inc. SEC filings index, EDGAR
• SEC Whistleblower Program
• Glancy Prongay Wolke & Rotter LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.